CMS HAS ANNOUNCED NEW PRELIMINARY MEDICARE PAYMENT RATES FOR LABORATORY SERVICES, SAVING TAXPAYERS AN ESTIMATED $1 BLN ANNUALLY, AND ANTICIPATES FINALIZING CY 2027 PAYMENT RATES FOR CLINICAL DIAGNOSTIC LABORATORY TESTS UNDER THE CLINICAL LABORATORY FEE SCHEDULE IN NOVEMBER 2026, WITH THE FINAL RATES GOING INTO EFFECT BEGINNING JANUARY 1, 2027

CMS HAS ANNOUNCED NEW PRELIMINARY MEDICARE PAYMENT RATES FOR LABORATORY SERVICES, SAVING TAXPAYERS AN ESTIMATED $1 BLN ANNUALLY, AND ANTICIPATES FINALIZING CY 2027 PAYMENT RATES FOR CLINICAL DIAGNOSTIC LABORATORY TESTS UNDER THE CLINICAL LABORATORY FEE SCHEDULE IN NOVEMBER 2026, WITH THE FINAL RATES GOING INTO EFFECT BEGINNING JANUARY 1, 2027

CMS HAS ANNOUNCED NEW PRELIMINARY MEDICARE PAYMENT RATES FOR LABORATORY SERVICES, SAVING TAXPAYERS AN ESTIMATED $1 BLN ANNUALLY, AND ANTICIPATES FINALIZING CY 2027 PAYMENT RATES FOR CLINICAL DIAGNOSTIC LABORATORY TESTS UNDER THE CLINICAL LABORATORY FEE SCHEDULE IN NOVEMBER 2026, WITH THE FINAL RATES GOING INTO EFFECT BEGINNING JANUARY 1, 2027

.@CMSGov Deputy Administrator Abe Sutton on what this means for everyday Americans: “Our state partners have shared with us that they expect this will help them expand access to drugs and preserve access to needed medications. That’s something that benefits the most vulnerable members of our society — the mother with a child who needs access to treatment, the person with a disability who depends on Medicaid, and the taxpayer asking whether their government truly values every hard-earned dollar they pay in taxes. Today, we answer them.”

CME Group is proud to be named by @BusinessInsider in America’s Most Innovative Businesses 2027—selected as 1 of 500 companies for our excellence in risk management and technology!